Zepbound vs Wegovy: Which Wins for Weight Loss in 2026?

Side-by-Side Comparison

The Mechanism Difference: One Receptor vs Two

To understand why Zepbound outperforms Wegovy on the scale, you need to understand what each drug is actually doing at the molecular level.

Wegovy (Semaglutide): GLP-1 Receptor Agonist

Semaglutide mimics glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after you eat. Binding to GLP-1 receptors does several things: it stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release (reducing liver glucose output), slows gastric emptying (so food stays in your stomach longer, reducing appetite), and signals satiety centers in the hypothalamus. The result is powerful appetite suppression with meaningful metabolic effects.

Zepbound (Tirzepatide): Dual GIP + GLP-1 Receptor Agonist

Tirzepatide was engineered as a single molecule that activates both GLP-1 receptors and glucose-dependent insulinotropic polypeptide (GIP) receptors simultaneously. GIP is secreted from intestinal K-cells and was traditionally considered a "weak" incretin with modest effects. But research has shown that activating the GIP receptor alongside GLP-1 produces a synergistic effect that exceeds what either pathway achieves alone.

The GIP component of tirzepatide appears to amplify fat mobilization from adipose tissue, enhance the GLP-1 receptor's effects on the hypothalamus, and modulate energy expenditure at the cellular level. There is also evidence that GIP receptor activation reduces the nausea associated with GLP-1 receptor stimulation — which may allow patients to better tolerate higher effective doses of tirzepatide compared to semaglutide.

This dual-receptor mechanism is why tirzepatide produces meaningfully greater weight loss than semaglutide at their respective maximum doses — not because it's a "stronger" GLP-1 drug, but because it's working through an additional biological pathway.

Weight Loss Data: What the Trials Show

STEP 1 Trial (Wegovy)

Published in the New England Journal of Medicine in 2021, STEP 1 enrolled 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related condition, without type 2 diabetes. After 68 weeks of semaglutide 2.4 mg/week versus placebo, participants on semaglutide lost an average of 14.9% of their body weight compared to 2.4% on placebo. Approximately 32% of participants lost ≥20% of body weight. These numbers were remarkable at the time and established semaglutide as a first-in-class obesity medication.

SURMOUNT-1 Trial (Zepbound)

Published in 2022, SURMOUNT-1 enrolled 2,539 adults with obesity or overweight plus comorbidities, without type 2 diabetes. After 72 weeks, participants receiving tirzepatide 15 mg/week lost an average of 20.9% of body weight, compared to 3.1% on placebo. At the 10 mg dose, average weight loss was 19.5%; at 5 mg, it was 15.0%. Crucially, 57% of participants on tirzepatide 15 mg lost ≥20% of body weight — a milestone previously only seen in bariatric surgery outcomes.

SURMOUNT-5: The First Head-to-Head Trial

SURMOUNT-5, results published in 2025, was the study the obesity medicine community had been waiting for: a direct, randomized, controlled head-to-head comparison of tirzepatide 15 mg versus semaglutide 2.4 mg in adults with obesity. After 72 weeks:

• Tirzepatide 15 mg: average 20.2% body weight reduction
• Semaglutide 2.4 mg: average 13.7% body weight reduction
• Tirzepatide produced ~47% more relative weight loss than semaglutide in this direct comparison
• Tirzepatide participants were more than twice as likely to achieve ≥25% body weight loss

The SURMOUNT-5 data effectively settled the head-to-head debate for average weight loss outcomes: at maximum approved doses, tirzepatide outperforms semaglutide. The caveat is that averages mask a wide distribution — some individuals respond far better to semaglutide, and the difference between poor responders and strong responders on either drug is significant.

Side Effect Comparison

Both drugs share a similar GI side effect profile, which is expected given that GLP-1 receptor activation slows gastric motility. The key question is whether the dual-receptor mechanism of tirzepatide changes the side effect picture — and the data suggests it does, modestly, in tirzepatide's favor.

Nausea and Vomiting

In SURMOUNT-1, nausea occurred in approximately 31% of participants on tirzepatide 15 mg vs 6% in the placebo group. In STEP 1, nausea occurred in approximately 44% of semaglutide participants. While these trials aren't directly comparable due to design differences, the pattern is consistent with preclinical evidence that GIP receptor activation may partially offset GLP-1-mediated nausea. In the head-to-head SURMOUNT-5 trial, GI side effects were broadly similar between groups, with tirzepatide showing slightly lower rates of nausea and vomiting.

Diarrhea and Constipation

Both drugs cause diarrhea in some patients early in dose escalation and constipation in others as the dose stabilizes. Neither drug has a clearly superior GI tolerability profile here — individual responses vary widely. Staying well hydrated, eating fiber-rich foods, and slowing dose escalation if symptoms are severe all apply equally to both medications.

Injection Site Reactions

Both use once-weekly subcutaneous injection delivered via pre-filled auto-injector pens. Injection site reactions (redness, bruising, mild pain) occur at similar rates. Zepbound's pen design changed slightly from the Mounjaro pen — some users report the Zepbound autoinjector is easier to use, though this is anecdotal.

Serious Risks (Both Drugs)

Both tirzepatide and semaglutide carry an FDA black box warning for thyroid C-cell tumors based on rodent studies. While this effect has not been confirmed in humans, both drugs are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). Both drugs are also associated with a small risk of acute pancreatitis — patients should be counseled to seek care for persistent severe abdominal pain.

Cost and Insurance in 2026

Cost remains one of the most significant practical factors separating Zepbound and Wegovy for most patients. Both drugs carry high list prices, but the real-world cost landscape is complex and evolving.

List Price

As of mid-2026, Wegovy carries a list price of approximately $1,349 per month (four auto-injector pens). Zepbound carries a slightly lower list price of approximately $1,059–$1,086 per month — Eli Lilly priced it below Wegovy at launch as a competitive move. Neither figure reflects what most patients actually pay.

Manufacturer Savings Programs

Eli Lilly's Zepbound savings card can bring out-of-pocket costs to approximately $549/month for commercially insured patients and around $399/month for uninsured patients who qualify. Novo Nordisk offers the NovoCare savings program for Wegovy, which can bring costs down to $0–$25/month for eligible commercially insured patients, or a flat $99/month for uninsured patients who meet income criteria.

Compounded Semaglutide — A Wegovy Cost Advantage

One significant real-world cost advantage for semaglutide is the availability of compounded versions. When the FDA declared Wegovy in shortage (a designation that has fluctuated since 2022), 503B compounding pharmacies were permitted to produce semaglutide injections at significantly lower cost — often $200–$500/month depending on the provider and dose. Compounded tirzepatide has also been available during shortage periods, but semaglutide compounding has been more widespread and has a longer track record with telehealth prescribers. As of 2026, both drugs have gone in and out of shortage status; verify current availability with your prescriber.

Insurance Coverage

Coverage for obesity medications remains inconsistent. As of 2026, Medicare Part D covers Wegovy for cardiovascular risk reduction in patients who meet SELECT trial criteria (BMI ≥27, established cardiovascular disease). Zepbound does not yet have the same cardiovascular outcomes labeling, which creates a meaningful insurance coverage gap for older patients and those with heart disease. Many commercial plans cover both with prior authorization; some cover neither. Always verify formulary status before choosing a medication.

Who Should Choose Zepbound vs Wegovy?

Consider Zepbound (tirzepatide) if:

• Your primary goal is maximum weight loss and you want the drug with the strongest average efficacy data
• You have obstructive sleep apnea — tirzepatide is the first GLP-1 drug to receive FDA approval for OSA (SURMOUNT-OSA trial)
• You have type 2 diabetes — tirzepatide (as Mounjaro) showed superior HbA1c reduction vs semaglutide in SURPASS-2
• You have experienced significant nausea on semaglutide and want to try the drug with potentially slightly better GI tolerability
• Your insurance covers Zepbound and the savings card brings your out-of-pocket to an acceptable level

Consider Wegovy (semaglutide) if:

• You have established cardiovascular disease — the SELECT trial's 20% MACE reduction gives semaglutide a proven cardiovascular benefit label that tirzepatide does not yet have
• You need Medicare coverage for an obesity medication — Wegovy's SELECT indication enables Part D coverage; Zepbound does not yet qualify
• Cost is a primary concern and you qualify for Novo Nordisk's $99/month program, or you have access to compounded semaglutide through a licensed telehealth provider
• You have had a good response to semaglutide in the past (e.g., on Ozempic for diabetes) and want to continue with a familiar molecule
• Supply chain concerns — semaglutide has had longer commercial availability and more robust distribution infrastructure in many regions

Frequently Asked Questions

Is Zepbound stronger than Wegovy?

On average weight loss, yes — the SURMOUNT-5 head-to-head trial showed tirzepatide 15 mg produces approximately 47% more relative weight loss than semaglutide 2.4 mg. However, "stronger" is not the same as "better for every patient." Individual responses vary significantly, and factors like cardiovascular history, insurance coverage, and tolerability all influence which drug is the better clinical choice for a given person.

Can I switch from Wegovy to Zepbound (or vice versa)?

Yes — switching between GLP-1 and GIP/GLP-1 medications is done regularly in clinical practice. There is no approved protocol for direct cross-titration; most physicians restart the new drug at the lowest dose and re-titrate up, which means a period of lower-dose exposure. Some patients who plateau on semaglutide show renewed weight loss after switching to tirzepatide, though this has not been studied in a controlled trial. Consult your prescriber before switching.

Does Wegovy protect the heart better than Zepbound?

Currently, yes — Wegovy has a specific FDA-approved cardiovascular risk reduction indication based on the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events (MACE) in non-diabetic adults with obesity and established cardiovascular disease. Tirzepatide's SURPASS-CVOT trial results are anticipated in 2026–2027. Until those results are published, semaglutide has a stronger evidentiary basis for cardiovascular protection. This is a clinically meaningful distinction for cardiologists and for Medicare coverage eligibility.

Which drug causes more muscle loss?

Both semaglutide and tirzepatide cause lean mass loss alongside fat loss, which is an inherent challenge with rapid weight reduction. Available data suggests the ratio of fat loss to lean mass loss is broadly similar between the two drugs, though some analysis of SURMOUNT and STEP trial body composition data suggests tirzepatide may preferentially spare slightly more lean mass relative to the total weight lost. Regardless of which drug you take, resistance training and adequate protein intake (1.2–1.6 g/kg body weight daily) are the most evidence-based strategies to preserve muscle during GLP-1-mediated weight loss.

More GLP-1 Comparisons

Looking at a different comparison? These guides cover related decisions:

• Ozempic vs Wegovy: Same Drug, Different Doses — What You Need to Know
• Semaglutide vs Tirzepatide: Full Mechanism and Trial Data Comparison
• GLP-1 Drugs vs Bariatric Surgery: STAMPEDE Trial and What the Data Shows